A Prospective, Single-center Investigation of the Impact of Antithrombotic Drugs and Cerebral Microbleeds on Cerebral Outcomes in Patients with Coronary Artery Stents - Antithrombotic Drugs and Cerebral Microbleeds in Coronary Artery Disease

The prevalence of intracerebral microbleeds (CMBs) was 33% (n=109), with a mean number of CMBs of 2.9+-3.6 (median 2, quartile range 1-3), of which 16 (15%) were multi-CMBs (>4). ICH occurred in 1 of 4 CMBs (1.1%), with no significant difference in ICH prevalence among the 3 groups. CMB was associated with all-cause mortality (non-CMB vs. CMB<5 vs. CMB>4, 3.6% vs. 12.0% vs. 6.3%, P=0.022).